Upstream Bio Inc. Common Stock (UPB)

About UPB

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was inco…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

75

Website

upstreambio.com/

Fundamentals

1-day range

$6.6$6.79

Market cap

$349.38M

P/E (trailing)

—

P/E (forward)

-2.28

EPS (trailing)

$-2.90

Dividend yield

—

Beta

2.07

Avg. volume

608.4K

Forecasts

8 analyst ratings

Upstream Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• UPB

  Upstream Bio Inc. Common Stock

  $6.68

  ▼ 1.62%
  Market cap $349.38MP/E —
  $5.85$33.68
• DMAC

  DiaMedica Therapeutics Inc. Common Stock

  $6.39

  ▼ 5.33%
  Market cap $351.32MP/E —
  $5.14$10.42
• ZNTL

  Zentalis Pharmaceuticals Inc. Common Stock

  $3.8

  ▼ 2.06%
  Market cap $331.02MP/E —
  $1.21$6.95
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $372.35MP/E —
  $2.53$5.45
• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $376.57MP/E —
  $7.05$17.15
• VNDA

  Vanda Pharmaceuticals Inc. Common Stock

  $5.29

  ▼ 2.76%
  Market cap $314.51MP/E —
  $4.27$9.94
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $391.42MP/E 18.65
  $4.3$9.51

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
  benzinga · 8/14/2026

Institutional Ownership

March 31, 2026

Total shares held

43.51M

Total value held

$391.54M

Institutional holders

136